Pentraxin Therapeutics Ltd is a University College London spin out company founded in 2001 by Professor Mark Pepys FRS. He is the Head of Medicine at UCL’s Royal Free Campus and the Director of the UCL Centre for Amyloidois and Acute Phase Proteins which contains the UK NHS National Amyloidosis Centre. Pentraxin holds the intellectual property and proprietary knowledge created by his research group. The company designs new treatments for systemic amyloidosis and the amyloid-related diseases, Alzheimer’s disease and type II diabetes, as well as targeting the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases. Development of these inventions is proceeding both within the UCL environment, supported by the Medical Research Council, and through extensive collaborations with GlaxoSmithKline, one of the world’s leading pharmaceutical companies.
You can find details of Pentraxin’s current R&D Programmes by clicking on the “R&D Programmes” tab above. The “News” tab will take you to the latest updates on Pentraxin’s research and collaborations and “Links” contains links to related sites.